CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 146 enrolled
Drug / intervention
Vitamin D3drug
Likely dose
Vitamin D3 200,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05795933
NCT05795933Phase 3Completed

Efficacy of Vitamin D Supplementation for Children With Bronchiolitis at Sohag University Hospital

Sohag University·interventional·Posted Apr 3, 2023·Updated Oct 29, 2024

In Brief

A Phase 3 clinical trial evaluating Vitamin D3 for Bronchiolitis. Completed, enrolled 146 participants across 1 site.

Detailed Summary

Vitamin D plays an important role in enhancing mucosal immune defense, decreasing excessive inflammation, and increasing mucociliary clearance. Experimental studies have shown that vitamin D reduces inflammation of epithelial cells in airways infected with Respiratory Syncytial Virus and confers antiviral effects. Furthermore, several studies have shown lower serum vitamin D levels in hospitalized children with bronchiolitis. However, studies on the efficacy of Vitamin D supplementation for children with bronchiolitis are scarce with inconsistent findings. In this study, we aim to evaluate the efficacy of vitamin D supplementation in children with bronchiolitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchiolitis
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedApr 3, 2023
Enrollment StartApr 1, 2023
Primary CompletionJun 22, 2024
Study CompletionJul 14, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.2 years ago

Interventions

Vitamin D3drug

A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission